Phosphodiesterase-1 inhibitory activity of two flavonoids isolated from pistacia integerrima J. L. Stewart galls

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Rauf, Abdur ^a   Saleem, Muhammad ^b   Uddin, Ghias ^a   Siddiqui, Bina S ^b   Khan, Haroon ^c   Raza, Muslim ^a   Hamid, Syeda Zehra ^a   Khan, Ajmal ^b   Maione, Francesco ^d   Mascolo, Nicola ^d   De Feo, Vincenzo ^e  

^a UNIVERSITY OF PESHAWAR   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

^c ABDUL WALI KHAN UNIVERSITY   (Pakistan)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,5,7,4' TETRAHYDROXYFLAVANONE; BETA STIGMASTEROL; CAFFEINE; FLAVONOID; METHANOL; NARINGENIN; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PISTACIA INTEGERRIMA EXTRACT; PISTAGREMIC ACID; PLANT EXTRACT; SITOSTEROL; STIGMASTEROL; UNCLASSIFIED DRUG;

AIRWAY SMOOTH MUSCLE CELL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG ISOLATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DOCKING; PISTACIA; PISTACIA INTEGERRIMA; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SOLVENT EXTRACTION;

EID: 84928526289     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/506564     Document Type: Article

References (43)

1. M. Bozorgi, Z. Memariani, M. Mobli, M. H. Salehi Surmaghi, M. R. Shams-Ardekani, and R. Rahimi, "Five Pistacia species (P. vera, P. atlantica, P. terebinthus, P. khinjuk, and P. lentiscus): a review of their traditional uses, phytochemistry, and pharmacology, " TheScientificWorld Journal, vol. 2013, Article ID219815, 33 pages, 2013.
2. S. Ahmad, M. Ali, S. H. Ansari, and F. Ahmed, "Phytoconstituents from the galls of Pistacia integerrima Stewart, " Journal of Saudi Chemical Society, vol. 14, no. 4, pp. 409-412, 2010.
3. A. S. Upadhye and A. A. Rajopadhye, "Pharmacognostic and phytochemical evaluation of leaf galls of Kakadshringi used in Indian system of medicine, " Journal of Scientific and Industrial Research, vol. 69, no. 9, pp. 700-704, 2010.
4. A. V. S. Kottakkal, Indian Medicinal Plants, vol. 4, Orient Longman, New Delhi, India, 1995.
5. S. K. Bhattacharjee, Handbook of Medicinal Plants, Pointer Publishers, Jaipur, India, 2000.
6. N. S. Ahmad, M. Farman, M. H. Najmi, K. B. Mian, and A. Hasan, "Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout, " Journal of Ethnopharmacology, vol. 117, no. 3, pp. 478-482, 2008.
7. G. Uddin and A. Rauf, "In vitro antimicrobial profile of Pistacia integerrima galls Stewart, " Middle-East Journal of Medicinal Plants Research, vol. 1, pp. 36-40, 2012.
8. A. Rauf, G. Uddin, M. Arfan, and N. Muhammad, "Chemical composition and biological screening of essential oils from Pistacia integerrima, " African Journal of Pharmacy and Pharmacology, vol. 7, no. 20, pp. 1220-1224, 2013.
9. S. Adusumalli, P. Madan Ranjit, and M. SankaranarayanHarish, "Antiasthmatic activity of aqueous extract of Pistacia integerrima galls, " International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, supplement 2, pp. 116-121, 2013.
10. R. L. Shirole, N. L. Shirole, A. A. Kshatriya, R. Kulkarni, and M. N. Saraf, "Investigation into the mechanism of action of essential oil of Pistacia integerrima for its antiasthmatic activity, " Journal of Ethnopharmacology, vol. 153, no. 3, pp. 541-551, 2014.
11. U. P. Joshi and S. H. Mishra, "In vitro antioxidant and hepatoprotective activity of isolated compounds from Pistacia integerrima, " Australian Journal of Medical Herbalism, vol. 22, no. 3, pp. 94-99, 2010.
12. Z. Ullah, R. Mehmood, M. Imran, A. Malik, and R. A. Afzal, "New acylated oligosaccharides fromPistacia integerrima, " Natural Product Research, vol. 27, no. 21, pp. 2027-2032, 2013.
13. L. M. Fabbri, P. M. Calverley, J. L. Izquierdo-Alonso et al., "Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials, " The Lancet, vol. 374, no. 9691, pp. 695-703, 2009.
14. L. G. Franciosi, Z. Diamant, K. H. Banner et al., "Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials, " The Lancet Respiratory Medicine, vol. 1, no. 9, pp. 714-727, 2013.
15. M. Della Greca, P. Monaco, and L. Previtera, "Stigmasterols from Typha latifolia, " Journal of Natural Products, vol. 53, no. 6, pp. 1430-1435, 1990.
16. S. Seo, Y. Tomita, K. Tori, and Y. Yoshimura, "Determination of the absolute configuration of a secondary hydroxy group in a chiral secondary alcohol using glycosidation shifts in carbon-13 nuclearmagnetic resonance spectroscopy, " Journal of the American Chemical Society, vol. 100, no. 11, pp. 3331-3339, 1978.
17. H. Ullah, A. Rauf, Z. Ullah et al., "Density functional theory and phytochemical study of Pistagremic acid, " Spectrochimica Acta. Part A: Molecular and Biomolecular Spectroscopy, vol. 118, pp. 210-214, 2014.
18. R. Mamillapalli, R. Haimovitz, M. Ohad, and M. Shinitzky, "Enhancement and inhibition of snake venom phosphodiesterase activity by lysophospholipids, " FEBS Letters, vol. 436, no. 2, pp. 256-258, 1998.
19. J. López-Gómez, M. J. Costas, J. M. Ribeiro et al., "Glycineenhanced inhibition of rat liver nucleotide pyrophosphatase/phosphodiesterase-I by EDTA: a full account of the reported inhibition by commercial preparations of acidic fibroblast growth factor (FGF-1), " FEBS Letters, vol. 421, no. 1, pp. 77-79, 1998.
20. V. U. Ahmad, M. A. Abbasi, H. Hussain et al., "Phenolic glycosides from Symplocos racemosa: natural inhibitors of phosphodiesterase I, " Phytochemistry, vol. 63, no. 2, pp. 217-220, 2003.
21. N. Guex and M. C. Peitsch, "SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling, " Electrophoresis, vol. 18, no. 15, pp. 2714-2723, 1997.
22. Z. Li, H. Wan, Y. Shi, and P. Ouyang, "Personal experiencewith four kinds of chemical structure drawing software: review on chemdraw, chemwindow, ISIS/draw, and chemsketch, " Journal of Chemical Information and Computer Sciences, vol. 44, no. 5, pp. 1886-1890, 2004.
23. M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeerschd, E. Zurek, and G. R. Hutchison, "Avogadro: an advanced semantic chemical editor, visualization, and analysis platform, " Journal of Cheminformatics, vol. 4, article 17, 2012.
24. O. Trott and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, " Journal of Computational Chemistry, vol. 31, pp. 455-461, 2010.
25. K. C. Hsu, Y. F. Chen, S. R. Lin, and J. M. Yang, "Igemdock: a graphical environment of enhancing gemdock using pharmacological interactions and post-screening analysis, " BMC Bioinformatics, vol. 12, supplement 1, article S33, 2011.
26. M. W. Chang, C. Ayeni, S. Breuer, and B. E. Torbett, "Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina, " PLoS ONE, vol. 5, no. 8, Article ID e11955, 2010.
27. R. B. Jacob, T. Andersen, and O. M. McDougal, "Accessible highthroughput virtual screening molecular docking software for students and educators, " PLoS Computational Biology, vol. 8, no. 5, Article ID e1002499, 2012.
28. A. Kumar, S. Kumar, S. Jain, P. Kumar, and R. Goyal, "Study of binding of pyridoacridine alkaloids on topoisomerase II using in silico tools, " Medicinal Chemistry Research, vol. 22, no. 11, pp. 5431-5441, 2013.
29. N. Muhammad, R. Lal Shrestha, A. Adhikari et al., "First evidence of the analgesic activity of govianadine, an alkaloid isolated from Corydalis govaniana Wall, " Natural Product Research, vol. 29, no. 5, pp. 430-437, 2014.
30. F. Orallo, M. Camiña, E. Alvarez, H. Basaran, and C. Lugnier, "Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (±)-naringenin, " Planta Medica, vol. 71, no. 2, pp. 99-107, 2005.
31. M. K. Khan, Zill-E-Huma, and O. Dangles, "A comprehensive review on flavanones, the major citrus polyphenols, " Journal of Food Composition and Analysis, vol. 33, no. 1, pp. 85-104, 2014.
32. K. Karthic, K. S. Kirthiram, S. Sadasivam, B. Thayumanavan, and T. Palvannan, "Identification of α amylase inhibitors from Syzygium cumini Linn seeds, " Indian Journal of Experimental Biology, vol. 46, no. 9, pp. 677-680, 2008.
33. A. Dan, T. Shiyama, K. Yamazaki et al., "Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and-5, " Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 18, pp. 4085-4090, 2005.
34. Y. H. Jeon, Y. S. Heo, C. M. Kim et al., "Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development, " Cellular and Molecular Life Sciences, vol. 62, no. 11, pp. 1198-1220, 2005.
35. P. Crosswhite and Z. Sun, "Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension, " Hypertension, vol. 61, no. 3, pp. 585-592, 2013.
36. J. A. Beavo, "Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms, " Physiological Reviews, vol. 75, no. 4, pp. 725-748, 1995.
37. H. Nguyen and A. M. Amanullah, "Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease, " Reviews in Cardiovascular Medicine, vol. 15, pp. 158-167, 2014.
38. S. D. Rybalkin, I. Rybalkina, J. A. Beavo, and K. E. Bornfeldt, "Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation, " Circulation Research, vol. 90, no. 2, pp. 151-157, 2002.
39. D. Marx, M. Tassabehji, S. Heer, K.-B. Hüttenbrink, and I. Szelenyi, "Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids, " Pulmonary Pharmacology and Therapeutics, vol. 15, no. 1, pp. 7-15, 2002.
40. R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska et al., "Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy, " Circulation, vol. 115, no. 17, pp. 2331-2339, 2007.
41. R. T. Zamanian, K. T. Kudelko, Y. K. Sung, V. de Jesus Perez, J. Liu, and E. Spiekerkoetter, "Current clinical management of pulmonary arterial hypertension, " Circulation Research, vol. 115, no. 1, pp. 131-147, 2014.
42. R. A. Laskowski and M. B. Swindells, "LigPlot+:multiple ligandprotein interaction diagrams for drug discovery, " Journal of Chemical Information and Modeling, vol. 51, no. 10, pp. 2778-2786, 2011.
43. M. Umamaheswari, A. Madeswaran, K. Asokkumar, T. Sivashanmugam, V. Subhadradevi, and P. Jagannath, "Discovery of potential xanthine oxidase inhibitors using in silico docking studies," Der Pharma Chemica, vol. 3, no. 5, pp. 240-247, 2011.